InFlectis BioScience has announced the publication of a pivotal study in Life Science Alliance, showcasing the therapeutic potential of IFB-088 in treating amyotrophic lateral sclerosis (ALS). The research highlights IFB-088's ability to reduce TDP-43 cytoplasmic mislocalization, a key factor in 97% of ALS cases, and improve motor neuron survival across various ALS models.
The study, a collaboration with European academic and clinical institutions, demonstrates that IFB-088 not only mitigates mitochondrial oxidative stress and TDP-43 accumulation but also enhances motor function and survival in preclinical models. Dr. Emmanuelle Abgueguen, the lead author, emphasizes the drug's unique mechanism of action, which targets the cellular stress response broadly, potentially offering wider benefits than current therapies focusing on single genes.
With a completed Phase II trial in bulbar-onset ALS patients and promising preclinical results, InFlectis BioScience is poised to advance IFB-088 into Phase 2B trials, pending partnership or investment support. Dr. Pierre Miniou, COO at InFlectis, underscores the importance of such collaborations in the current economic climate to bring this promising treatment to ALS patients.
The full findings are available in Life Science Alliance, marking a significant step forward in the quest for effective ALS therapies.
